JP2025513799A5 - - Google Patents

Info

Publication number
JP2025513799A5
JP2025513799A5 JP2024559409A JP2024559409A JP2025513799A5 JP 2025513799 A5 JP2025513799 A5 JP 2025513799A5 JP 2024559409 A JP2024559409 A JP 2024559409A JP 2024559409 A JP2024559409 A JP 2024559409A JP 2025513799 A5 JP2025513799 A5 JP 2025513799A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tdp
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513799A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/059222 external-priority patent/WO2023194565A1/en
Publication of JP2025513799A publication Critical patent/JP2025513799A/ja
Publication of JP2025513799A5 publication Critical patent/JP2025513799A5/ja
Pending legal-status Critical Current

Links

JP2024559409A 2022-04-08 2023-04-06 抗tdp-43結合分子 Pending JP2025513799A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22167341 2022-04-08
EP22167341.1 2022-04-08
EP23164858.5 2023-03-28
EP23164858 2023-03-28
PCT/EP2023/059222 WO2023194565A1 (en) 2022-04-08 2023-04-06 Anti-tdp-43 binding molecules

Publications (2)

Publication Number Publication Date
JP2025513799A JP2025513799A (ja) 2025-04-30
JP2025513799A5 true JP2025513799A5 (https=) 2026-04-13

Family

ID=86099758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559409A Pending JP2025513799A (ja) 2022-04-08 2023-04-06 抗tdp-43結合分子

Country Status (10)

Country Link
US (1) US20260043816A1 (https=)
EP (1) EP4504775A1 (https=)
JP (1) JP2025513799A (https=)
KR (1) KR20250004705A (https=)
CN (1) CN119156401A (https=)
AU (1) AU2023250038A1 (https=)
CA (1) CA3246990A1 (https=)
IL (1) IL316153A (https=)
MX (1) MX2024012382A (https=)
WO (1) WO2023194565A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2026013218A1 (en) * 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8354236B2 (en) 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
WO2008042190A2 (en) 2006-09-29 2008-04-10 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US8940872B2 (en) * 2007-07-06 2015-01-27 Tokyo Metropolitan Institute Of Medical Science Antibody binding specifically to TDP-43 aggregate
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
US9587014B2 (en) * 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
JP6325463B2 (ja) 2012-03-16 2018-05-16 コヴァジェン アクチェン ゲゼルシャフト 抗腫瘍活性を有する新規結合分子
WO2016205522A2 (en) * 2015-06-19 2016-12-22 Saint Louis University Antibodies recognizing phosphorylation at specific amino acid residues of transactive response dna-binding protein 43
WO2018218352A1 (en) * 2017-05-30 2018-12-06 The University Of British Columbia Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
EP3894433A4 (en) * 2018-12-14 2022-08-31 The University of British Columbia Antibodies to misfolded tdp-43 and methods of use
AU2020278907A1 (en) 2019-05-23 2022-01-20 Ac Immune Sa Anti-TDP-43 binding molecules and uses thereof
AU2021265165A1 (en) * 2020-04-29 2022-12-08 Promis Neurosciences Inc. Single chain antibodies and intrabodies to misfolded TDP-43 and methods of use
TW202221026A (zh) * 2020-08-14 2022-06-01 瑞士商Ac 免疫有限公司 人源化抗tdp-43結合分子及其用途

Similar Documents

Publication Publication Date Title
JP7399096B2 (ja) 神経変性を検出するためのアッセイ
JP7159185B2 (ja) 抗phf-タウ抗体及びその使用
EP2539366B1 (en) Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
AU2021204800A1 (en) Humanized anti-tau antibodies
CA2630344C (en) Improved protofibril selective antibodies and the use thereof
JP2022533432A5 (https=)
AU2020245031B2 (en) Antibodies to pyroglutamate amyloid-β and uses thereof
CN114008073B (zh) 抗tdp-43结合分子及其用途
JP2017521097A5 (https=)
JP2025513799A5 (https=)
RU2014144331A (ru) Гуманизированное тау-антитело
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
JP2020511976A (ja) タウに特異的に結合する結合分子
JP2023537761A5 (https=)
JP2025507569A5 (https=)
CN110320368A (zh) 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
JP2025178565A (ja) 診断のための新規分子
JP2025513799A (ja) 抗tdp-43結合分子
Islam et al. Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates
TW201840583A (zh) 對β-類澱粉肽的初原纖維形式具有特異性的抗體之神經細胞保護作用
WO2025037271A1 (en) Plasma assay for detecting cns-derived tau peptides
JP6416871B2 (ja) 生体サンプル中のaSyn特異的抗体を検出する方法
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
TW202334200A (zh) 抗澱粉樣蛋白β抗體及其使用方法
CN118201637A (zh) 治疗Tau病理的方法